MBX Biosciences Breaking News
September 21, 2025
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE)
Positive findings in bone and kidney biomarkers
All patients completed the 12-week AvailTM trial and 94% entered the OLE
Once-weekly canvuparatide was generally well tolerated, with no treatment-related serious adverse events or discontinuations during the 12-week trial
Preparation underway to initiate Phase 3 trial in 2026
Phase 2 Avail Topline Results are in the full press release below
Back to News